Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
1.380
+0.020 (1.47%)
At close: Mar 3, 2026, 4:00 PM EST
1.370
-0.010 (-0.72%)
After-hours: Mar 3, 2026, 7:04 PM EST
RANI Employees
As of December 31, 2024, Rani Therapeutics Holdings had 106 total employees, including 105 full-time and 1 part-time employees. The number of employees decreased by 34 or -24.29% compared to the previous year.
Employees
106
Change (1Y)
-34
Growth (1Y)
-24.29%
Revenue / Employee
$11,321
Profits / Employee
-$267,123
Market Cap
167.70M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 106 | -34 | -24.29% | 105 | 1 |
| Dec 31, 2023 | 140 | -23 | -14.11% | 140 | 0 |
| Dec 31, 2022 | 163 | 49 | 42.98% | 163 | 0 |
| Dec 31, 2021 | 114 | 43 | 60.56% | 114 | 0 |
| Sep 30, 2021 | 91 | 20 | 28.17% | 91 | 0 |
| Jun 30, 2021 | 78 | - | - | 78 | 0 |
| Mar 31, 2021 | 71 | - | - | 71 | 0 |
| Dec 31, 2020 | 71 | - | - | 71 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Sangamo Therapeutics | 183 |
| Fate Therapeutics | 181 |
| Innate Pharma | 174 |
| ProQR Therapeutics | 166 |
| Caribou Biosciences | 147 |
| Compugen | 74 |
| Milestone Pharmaceuticals | 33 |
RANI News
- 4 weeks ago - Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer - GlobeNewsWire
- 7 weeks ago - Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen - GlobeNewsWire
- 3 months ago - Rani Therapeutics to Participate in the Evercore Healthcare Conference - GlobeNewsWire
- 4 months ago - Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewsWire
- 4 months ago - Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025 - GlobeNewsWire
- 4 months ago - Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors - GlobeNewsWire
- 4 months ago - Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai - Seeking Alpha